MDXG Mimedx Group Inc
Price (delayed)
$8.12
Market cap
$1.2B
P/E Ratio
28
Dividend/share
N/A
EPS
$0.29
Enterprise value
$1.11B
MiMedx is an industry leader in utilizing birth tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare.
Highlights
The debt has plunged by 62% YoY
Mimedx Group's equity has increased by 35% YoY and by 7% QoQ
The stock's price to earnings (P/E) is 65% more than its last 4 quarters average of 17.0
Mimedx Group's EPS has shrunk by 54% QoQ and by 28% YoY
Key stats
What are the main financial stats of MDXG
Market
Valuations
Earnings
Shares outstanding
147.37M
Market cap
$1.2B
Enterprise value
$1.11B
Price to earnings (P/E)
28
Price to book (P/B)
6.18
Price to sales (P/S)
3.42
EV/EBIT
18.92
EV/EBITDA
16.82
EV/Sales
3.18
Revenue
$348.88M
Gross profit
$288.81M
Operating income
$58.3M
Net income
$42.42M
EBIT
$58.72M
EBITDA
$66.07M
Free cash flow
$64.52M
Per share
Balance sheet
Liquidity
EPS
$0.29
EPS diluted
$0.28
Free cash flow per share
$0.44
Book value per share
$1.31
Revenue per share
$2.37
TBVPS
$1.58
Total assets
$263.92M
Total liabilities
$70.81M
Debt
$18.83M
Equity
$193.11M
Working capital
$146.29M
Debt to equity
0.1
Current ratio
4.21
Quick ratio
3.51
Net debt/EBITDA
-1.3
Margins
Efficiency
Dividend
EBITDA margin
18.9%
Gross margin
82.8%
Net margin
12.2%
Operating margin
16.7%
Return on assets
17.7%
Return on equity
24.3%
Return on invested capital
54.6%
Return on capital employed
26.9%
Return on sales
16.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MDXG stock price
How has the Mimedx Group stock price performed over time
Intraday
4.24%
1 week
0.25%
1 month
-0.37%
1 year
1.5%
YTD
-15.59%
QTD
-15.59%
Financial performance
How have Mimedx Group's revenue and profit performed over time
Revenue
$348.88M
Gross profit
$288.81M
Operating income
$58.3M
Net income
$42.42M
Gross margin
82.8%
Net margin
12.2%
The operating income has soared by 57% YoY but it fell by 7% QoQ
The net margin has plunged by 53% from the previous quarter and by 33% YoY
MDXG's net income has shrunk by 52% QoQ and by 27% YoY
The operating margin has grown by 45% YoY but it has contracted by 9% from the previous quarter
Growth
What is Mimedx Group's growth rate over time
Valuation
What is Mimedx Group stock price valuation
P/E
28
P/B
6.18
P/S
3.42
EV/EBIT
18.92
EV/EBITDA
16.82
EV/Sales
3.18
The stock's price to earnings (P/E) is 65% more than its last 4 quarters average of 17.0
Mimedx Group's EPS has shrunk by 54% QoQ and by 28% YoY
Mimedx Group's equity has increased by 35% YoY and by 7% QoQ
The P/B is 3.4% lower than the last 4 quarters average of 6.4
The P/S is 27% higher than the 5-year quarterly average of 2.7 and 7% higher than the last 4 quarters average of 3.2
MDXG's revenue is up by 9% YoY
Efficiency
How efficient is Mimedx Group business performance
MDXG's return on invested capital has surged by 96% year-on-year but it is down by 3.4% since the previous quarter
Mimedx Group's return on sales has surged by 93% YoY but it has decreased by 12% QoQ
Mimedx Group's return on equity has shrunk by 88% YoY and by 55% QoQ
MDXG's ROA has shrunk by 53% QoQ and by 41% YoY
Dividends
What is MDXG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MDXG.
Financial health
How did Mimedx Group financials performed over time
The total liabilities has contracted by 26% YoY but it has grown by 13% from the previous quarter
The quick ratio has increased by 19% YoY and by 2.9% QoQ
The debt is 90% less than the equity
MDXG's debt to equity has dropped by 71% year-on-year and by 9% since the previous quarter
The debt has plunged by 62% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.